Networks and Funding

Research networks

Networks are key to our research and diagnostic studies

The Clinical HIV Research Unit (CHRU) is part of several major international networks involved with addressing global health priorities and moving science forward. These networks are also primary sources of grants and funding and enable collaborations for clinical trials.

Networks that CHRU is part of include:

  • The National Institute of Allergy and Infectious Diseases (NIAID)directs and manages grants, contracts and cooperative agreements that support research at academic and research institutions internationally, including CHRU, through the Division of AIDS (DAIDS).
  • The COVID-19 Prevention Network (CoVPN) which was formed by NIAID at the US National Institutes of Health to respond to the global coronavirus pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The CoVPN is comprised of the partners listed below.
  • The AIDS Clinical Trials Group (ACTG) was established in 1987 to broaden the scope of the AIDS research effort of the National Institute of Allergy and Infectious Diseases (NIAID). The ACTG supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care, and training/education in their communities.
  • The HIV Prevention Trials Network (HPTN)is a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of interventions designed to prevent the transmission of HIV.
  • The AIDS Malignancy Consortium(AMC) is a National Cancer Institute (NCI)-supported clinical trials group, founded in 1995 to support innovative trials for AIDS-associated malignancies. It has 15 main Clinical Trials Sites and their affiliates, and an operations and statistical center.
  • The International Maternal Paediatric Adolescent AIDS Clinical Trials Network’s (IMPAACT) mission is to significantly decrease incident HIV and HIV-associated infections and to decrease mortality and morbidity due to HIV and HIV-associated infections and co-morbidities among infants, children, adolescents and pregnant/postpartum women.
  • The Insight Network is a leading provider of private healthcare in the UK with a proud heritage and experience of running successful private clinics. It has an established network of therapists  in the UK who offer evidence-based therapies in an out-patient setting to help resolve a range of common issues we face in our day-to-day lives, such as stress, depression, anxietyand eating disorders.
  • The PanACEA Network brings together a group of scientists from more than 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service who are working to deal with the global pandemic of tuberculosis and find new tools to control this disease. New drugs are central to any control strategy and the fastest route to tuberculosis elimination.
  • The TB Sequel Network is a research consortium built on pre-existing research collaborations within the TTU-TB of the German Center for Infection Research (DZIF) and between LMU and different African Sites. It has brought together a number of African partners from countries including South Africa with a high prevalence of TB and from academic institutions with a track-record in TB research. Each network partner has both the foundation for clinical research as well as specific and complementary areas of expertise.
  • TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.
  • The International Union against Tuberculosis and Lung Disease is an influential network of members, including over 850 staff based in 10 offices, and 25,000 rural health care providers, 15,000 community volunteers and thousands of partner organisations worldwide. It is a global scientific organisation with the mission to improve health among people living in poverty.

Track record and successful grant applications

Our track record with European researchers has led to successful grant applications through the German Federal Ministry of Education and Research and the EDCTP. The focus of these grants is tuberculosis(TB) – basic sciences, diagnostics, treatment and outcomes as well as socio-economic aspects associated with TB.

CHRU also works with the TB Alliance, the TB Union and more recently USAID, in the expansion of TB treatment trials and new drug development studies in both sensitive and multi-drug resistant (MDR) TB.

CHRU investigators have all played significant leading roles in the scientific agenda of DAIDS, participating in both administrative and scientific DAIDS committees.  The site has completed over 110 antiretroviral therapy studies in phase I-III research. 

CHRU has met the aims of the ACTG network to date and remains aligned with its future research agenda which include:

  • Defining the use of antiretroviral therapy in first, second and third-line, patterns of HIV drug resistance and cost of resistance testing, and nurse initiated and monitored antiretroviral therapy
  • Toxicities of antiretroviral therapy
  • Defining the timing of HIV antiretroviral therapy in participants presenting with Tuberculosis drug interactions between TB and HIV medicines and overlapping toxicities
  • Defining the role of novel diagnostic tests targeting the early diagnosis of Tuberculosis
  • Development of the strategic policy guidelines and costing models for the roll-out of antiretroviral treatment to 2017, and the implementation of GeneXpert™ throughout the national program in South Africa
  • Antiretroviral treatment adherence and improvements in loss-to-follow-up
  • Patterns of Viral Hepatitis and HIV co-infection (predominantly Hepatitis B and C), genotyping and drug resistance and
  • Patterns of Human Papilloma Virus (HPV), cervical dysplasia and cervical cancer including early diagnosis and treatment options and outcomes.